TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27893182
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (300 mg)
Study: 27893182
Drug: Rivaroxaban (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (40 mg)
Study: 27893182
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (300 mg) with clarithromycin
Study: 27893182
Drug: Rivaroxaban (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (40 mg) with clarithromycin
Study: 21514308
Drug: Acute angiotensin
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute angiotensin II receptor blocker (ARB; 600 mg irbesartan)
Study: 8636182
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg/kg body-weight, intravenously before tourniquet release and repeated three hours later)
Study: 24274030
Drug: Hydrogen-enriched solution
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen-enriched solution (H2‐HD)
Study: 14613506
Drug: Standard solution
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard solution
Study: 17414000
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (antipyretic drugs and/or surface cooling techniques)
Study: 3446275
Drug: Practolol at
Normalized name: practolol
DrugBank: Practolol (DB01297)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol at 200 mg bd
Study: 29540274
Drug: Quercetin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (1 g/d)
Study: 26717881
Drug: Nicotine (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (0.1, 0.2, 0.3, or 0.4 mg doses)
Study: 18580398
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OC) - Lo/Ovral (30 microg of ethinyl estradiol and 0.3 mg of norgestrel)
Study: 16776446
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) 300 mg
Study: 14653287
Drug: No surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No surface treatment (control)
Study: 10334255
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (sulphasalazine, methotrexate, hydroxychloroquine, and prednisolone)
Study: 10334255
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug therapy (sulphasalazine, with or without methotrexate and prednisolone)
Study: 1673592
Drug: Vecuronium 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.04 mg/kg
Study: 1673592
Drug: Vecuronium 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.07 mg/kg
Study: 29773176
Drug: Zinc, magnesium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc, magnesium, and chromium supplementation (300 mg magnesium, 600 μg chromium, 36 mg zinc per day)
Study: 26854810
Drug: Maraviroc 150mg
Normalized name: MARAVIROC 150MG TAB
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc 150mg once daily with darunavir/ritonavir
Study: 26854810
Drug: Tenofovir/emtricitabine once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir/emtricitabine once daily with darunavir/ritonavir
Study: 18768506
Drug: IgA antibody
Normalized name: Tissue transglutaminase IgA antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgA antibody to Chlamydia trachomatis
Study: 15857076
Drug: Antagonist Tooth
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antagonist Tooth (AT)
Study: 12423714
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg 3 times daily)
Study: 10412786
Drug: Prednisone (dose-dependent)
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (dose-dependent)
Study: 10412786
Drug: Overall immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall immunosuppressive therapy
Study: 7567321
Drug: Extended intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended intervention (hospital packet + oral and written advice at 2 weeks, 2, 4, and 6 months)
Study: 2145235
Drug: enoximone, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: enoximone, 150 mg t.d.s.
Study: 7387340
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of haloperidol on day 1, increasing increments of 20 mg daily, maximum 100 mg daily on day 5
Study: 7387340
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of haloperidol on day 1, increasing increments of 10 mg daily, maximum 100 mg daily on day 10
Study: 7387340
Drug: Fixed dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dosage of 10 mg daily for ten days
Study: 6133525
Drug: Astemizole (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole (single administration)
Study: 6133525
Drug: Astemizole (seven
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole (seven days of treatment)
Study: 6133525
Drug: Placebo (seven
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (seven days of treatment)
Study: 30959123
Drug: Post-neoAS, pre-RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-neoAS, pre-RT PSA level >0.1 ng/mL
Study: 30148430
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 2.5% cross-linked polyacrylamide hydrogel (PAAG), 3 ml, up to two injections 1 month apart.
Study: 24968790
Drug: HS219 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS219 (40 mg chitosan‐loaded chewing gum)
Study: 18827119
Drug: 3-mg drospirenone/20-microgram
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-mg drospirenone/20-microgram ethinyl estradiol 24/4 regimen
Study: 14628974
Drug: Risperidone (4-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (4-12 mg/day)
Study: 20859556
Drug: Mandibular implant-supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular implant-supported overdentures (IOD)
Study: 7310594
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no caffeine treatment)
Study: 29191325
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy with a sham procedure (right heart catheterization)
Study: 19562475
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for 16 sessions
Study: 22011688
Drug: Flupirtine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine (100 - 400 mg/d)
Study: 16965740
Drug: Fuzheng Kang'ai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzheng Kang'ai Granules combined with super-selective intra-arterial chemotherapy (EAP regime: VP(16) 100 mg/m(2) + epirubicin 60 mg/m(2) + carboplatin 200 mg/m(2))
Study: 16965740
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (super-selective intra-arterial chemotherapy only)
Study: 9290168
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (r‐HuEPO) treatment for 3 months
Study: 8497820
Drug: Theophylline treatment
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline treatment at a steady state plasma concentration of 17 mg/l
Study: 8497820
Drug: Theophylline treatment
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline treatment at a steady state plasma concentration of 10 mg/l
Study: 18790817
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (240 ml/day)
Study: 18790817
Drug: Vodka (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vodka (80 ml/day)
Study: 3462014
Drug: Histamine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine inhalation
Study: 1576060
Drug: Inhaled saline
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled saline (placebo)
Study: 3930437
Drug: Home-baked gliadin-containing
Normalized name: fish oil (containing omega-3 acids)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-baked gliadin-containing gluten-free bread, 6 slices daily for 6 weeks
Study: 31399454
Drug: Inspiratory Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory Muscle Training (IMT) - 8 weeks, twice a day, 5 days a week, with weekly physiotherapist visits; unsupervised IMT twice a day three times a week until follow-up at 6 months.
Study: 24372085
Drug: PC-tablet based
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC-tablet based intervention providing tailored information about breast cancer risk
Study: 22469449
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) 200 μg twice daily
Study: 22469449
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) 200 μg once daily
Study: 16102631
Drug: Prostaglandin E‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin E‐1 (PGE‐1) infusion for 20 days
Study: 16102631
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion for 20 days
Study: 16102631
Drug: Prostaglandin E‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin E‐1 (PGE‐1) infusion
Study: 12420730
Drug: Multi-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-drug regimen (intravenous cefuroxime 1.5 g and metronidazole 0.5 g preoperatively, and oral co-amoxiclav 375 mg 8-hourly postoperatively)
Study: 7719242
Drug: VBMCP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: VBMCP with intermittent high dose cyclophosphamide
Study: 8250105
Drug: Ivermectin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (12 mg)
Study: 3540871
Drug: codeine sulfate
Normalized name: Codeine Sulfate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: codeine sulfate 60 mg
Study: 3540871
Drug: naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen sodium 550 mg with codeine sulfate 60 mg
Study: 3540871
Drug: aspirin 650
Normalized name: aspirin 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin 650 mg
Study: 3540871
Drug: codeine-containing treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: codeine-containing treatments
Study: 27494629
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) applied to one painful finger in 3 sessions with one-week intervals.
Study: 27494629
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) applied to one painful finger.
Study: 22162577
Drug: Both agents
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both agents (low-dose tamoxifen and fenretinide)
Study: 21171297
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray specific immunotherapy
Study: 21171297
Drug: Sublingual specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual specific immunotherapy
Study: 18539093
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of vaginal misoprostol
Study: 15640254
Drug: Laparoscopic electrocautery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic electrocautery followed by clomiphene citrate (CC)
Study: 7914962
Drug: ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ursodeoxycholic acid plus norfloxacin (13‐15 mg/kg and 400 mg, daily)
Study: 2847465
Drug: 120 U(anti-FXa)/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 U(anti-FXa)/kg Fragmin injected twice daily
Study: 2847465
Drug: 240 U/kg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 U/kg, 12 h standard heparin as continuous infusion
Study: 29656504
Drug: MYL‐1501D and
Approvals — FDA: no, EMA: no, PMDA: no
Description: MYL‐1501D and Insulin glargine
Study: 28886751
Drug: Uva-ursi +
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uva-ursi + advice to take ibuprofen
Study: 28886751
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + advice to take ibuprofen
Study: 28886751
Drug: Uva-ursi +
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uva-ursi + no advice to take ibuprofen
Study: 28886751
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + no advice to take ibuprofen
Study: 24101768
Drug: High altitude
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High altitude treatment (≥ 2000 m)
Study: 24101768
Drug: Low altitude
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low altitude treatment (<2000 m)
Study: 18460557
Drug: COM (MET
Approvals — FDA: no, EMA: no, PMDA: no
Description: COM (MET 1000 mg BID, EX 10 microg BID)
Study: 18460557
Drug: MET (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET (1000 mg BID)
Study: 11078770
Drug: Atovaquone (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone (750 mg every 12 hours) and azithromycin (500 mg on day 1 and 250 mg per day thereafter) for seven days
Study: 11078770
Drug: Clindamycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (600 mg every 8 hours) and quinine (650 mg every 8 hours) for seven days
Study: 9329303
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A treatment (200,000 IU for infants, 400,000 IU for 1-4 year olds)
Study: 8518642
Drug: Community mother
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community mother intervention (monthly visits during the first year)
Study: 3559811
Drug: Inositol supplementation
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inositol supplementation (40 mg/kg every 6 hours)
Study: 21541451
Drug: Aerobic training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerobic training during hemodialysis, performed for 12 weeks, three times weekly.
Study: 19065902
Drug: Propyl gallate
Normalized name: Propyl Gallate
DrugBank: Propyl Gallate (DB12450)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propyl gallate (PrG) in combination with standard medication
Study: 19065902
Drug: Salvia composite
Normalized name: Salvia sclarea seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvia composite (SC) in combination with standard medication
Study: 16898901
Drug: Drug exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug exposure (provocation tests)
Study: 12860964
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 plus a 24-hour infusion of paclitaxel 135 mg/m2 (arm I)
Study: 12860964
Drug: Carboplatin area
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin area under the curve 7.5 intravenously plus paclitaxel 175 mg/m2 over 3 hours (arm II)
Study: 10026402
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antioxidants applied after UVR exposure
Study: 1649725
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate 300 mg
Study: 1649725
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate 600 mg
Study: 30353121
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (1,000 mg injections 3 times per week after each hemodialysis session)
Study: 27428608
Drug: Monsel solution
Normalized name: Monsel's solution
DrugBank: Ferric subsulfate (DB13885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monsel solution
Study: 4001759
Drug: Flunisolide nasal
Normalized name: flunisolide nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide nasal spray 0.025% (2 X 25 mcg in each nostril twice daily)
Study: 29231472
Drug: Lactulose oral
Normalized name: lactulose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose oral liquid, 20 to 30 mL once a day for 6 weeks.
Study: 23750468
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT; Coping Cat)
Study: 23750468
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (CBT + sertraline)
Study: 17019522
Drug: Calcium from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium from milk minerals (MM) 800 mg/day
Study: 17019522
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (CC) 800 mg/day
Study: 15242535
Drug: Single-dose nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose nevirapine (NVP) prophylaxis
Study: 10768912
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (group A)
Study: 10768912
Drug: No ACE
Normalized name: Amino Acetic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ACE inhibitors (group B)
Study: 10768912
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (group A) and No ACE inhibitors (group B)
Study: 8465450
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy three times a week for three weeks
Study: 8465450
Drug: Intermittent pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pneumatic compression for twenty minutes before occupational therapy
Study: 3080048
Drug: Antivenom given
Normalized name: ANTIVENIN,CROTALIDAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antivenom given by intravenous injection over 10 minutes
Study: 3080048
Drug: Antivenom diluted
Normalized name: ANTIVENIN,CROTALIDAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antivenom diluted and given as an intravenous infusion over 30 minutes
Study: 3080048
Drug: Antivenom treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antivenom treatment (both methods)
Study: 3080048
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of antivenom (not specifically tested in this trial)
Study: 24268111
Drug: Pregabalin 252
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 252 mg
Study: 6869761
Drug: Etomidate infusion
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etomidate infusion
Study: 10836011
Drug: Adjuvant postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant postoperative radiation or chemotherapy
Study: 1410069
Drug: d‐l fenfluramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐l fenfluramine hydrochloride (60 mg)
Study: 3882183
Drug: Oral 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5-fluorouracil (5 mg kg‐1 bodyweight) for 3 months
Study: 30946967
Drug: Black Strap
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black Strap Molasses (BSM) syrup (1 mL/kg body weight/day for 1 month)
Study: 30946967
Drug: Polyethylene Glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene Glycol (PEG) syrup (1 mL/kg body weight/day for 1 month)
Study: 28672136
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propofol and midazolam (PM group)
Study: 27240438
Drug: Control (antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (antiarrhythmic pharmacologic therapy)
Study: 19695832
Drug: Nutritional therapy
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional therapy group (NT group) received individual nutritional counseling and interventions, including oral nutritional supplements if appropriate.
Study: 19695832
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement group (ONS group) received oral nutritional supplements in addition to hospital meals without further instruction or counseling.
Study: 19695832
Drug: Nutritional therapy
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional therapy group (NT group)
Study: 19695832
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement group (ONS group)
Study: 8750403
Drug: PGE1 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE1 at 0.06 micro g/kg per minute for 3 postoperative days